Department of Rheumatology and Immunology, West China Hospital, Sichuan University, 37 Guoxue Lane, Chengdu, 610041, China.
Department of General Practice, General Practice Medical Center, West China Hospital, Sichuan university, Guoxue 37 Lane, Chengdu, 610041, China.
Adv Rheumatol. 2022 Jun 27;62(1):22. doi: 10.1186/s42358-022-00253-4.
This systematic review and meta-analysis aimed to investigate the incidence and risk of knee and hip replacement in patients with osteoarthritis (OA) treated with different medications.
OVID MEDLINE, OVID EMBASE, Cochrane and Web of Science electronic databases were searched from inception to May 4th, 2022. Clinical trials, including randomized controlled trials, cohort studies and case-control studies, were selected. The meta-analysis effect size was estimated using either incidence with 95% confidence intervals (CIs) or odds ratio (OR)/relative risk (RR) with 95% CIs. The risk of bias and heterogeneity among studies were assessed and analyzed.
Forty studies were included, involving 6,041,254 participants. The incidence of joint replacement in patients with OA varied according to the study design and treatments. The incidence of knee arthroplasty varied from 0 to 70.88%, while the incidence of hip arthroplasty varied from 11.71 to 96.43%. Compared to non-users, bisphosphonate users had a reduced risk of knee replacement (RR = 0.71, 95% CI: 0.66-0.77; adjusted hazard ratio [aHR] = 0.76, 95% CI: 0.70-0.83). Compared to intra-articular corticosteroid users, hyaluronic acid (HA) users had a higher risk of knee arthroplasty (RR = 1.76, 95% CI: 1.38-2.25). No publication bias was observed.
Bisphosphonate treatment is associated with a reduced risk of knee replacement. More studies are needed to validate our results due to the limited number of eligible studies and high heterogeneity among studies.
本系统评价和荟萃分析旨在调查不同药物治疗骨关节炎(OA)患者的膝关节和髋关节置换的发生率和风险。
从建库到 2022 年 5 月 4 日,我们在 OVID MEDLINE、OVID EMBASE、Cochrane 和 Web of Science 电子数据库中进行了检索。选择了临床试验,包括随机对照试验、队列研究和病例对照研究。使用发生率(95%置信区间[CI])或比值比(OR)/相对风险(RR)(95%CI)来估计荟萃分析的效应量。评估和分析了研究之间的偏倚和异质性。
共纳入 40 项研究,涉及 6041254 名参与者。OA 患者关节置换的发生率因研究设计和治疗方法而异。膝关节置换的发生率从 0 到 70.88%不等,而髋关节置换的发生率从 11.71%到 96.43%不等。与非使用者相比,双膦酸盐使用者膝关节置换的风险降低(RR=0.71,95%CI:0.66-0.77;调整后的危险比[aHR]=0.76,95%CI:0.70-0.83)。与关节内皮质类固醇使用者相比,透明质酸(HA)使用者膝关节置换的风险更高(RR=1.76,95%CI:1.38-2.25)。未观察到发表偏倚。
双膦酸盐治疗与膝关节置换风险降低相关。由于合格研究数量有限且研究之间存在高度异质性,需要更多的研究来验证我们的结果。